# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 05-13-2024 | 03-31-2024 | 10-Q | |
2 | 04-01-2024 | 12-31-2023 | 10-K | |
3 | 11-13-2023 | 09-30-2023 | 10-Q | |
4 | 09-15-2023 | 06-30-2023 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendiant Capital analyst Edward Woo initiates coverage on Mira Pharmaceuticals (NASDAQ:MIRA) with a Buy rating and announc...
MIRA Pharmaceuticals stock surged on Thursday following new preclinical data on Ketamir-2, MIRA's novel oral ketamine analo...
Latest positive preclinical data provides another step in the path to potential IND submission this year for novel ketamine ana...